Distribution of lymphoid neoplasms by category, diagnostic basis, city and sex, LSS 1950 to 1994
| . | Cases (%) . | |||||
|---|---|---|---|---|---|---|
| Lymphoid neoplasm category . | Total . | . | City . | Sex . | ||
| Histologically verified . | Nagasaki . | Hiroshima . | Female . | Male . | ||
| Hodgkin lymphoma | 15 (2.7) | 10 (66.7) | 5 (2.8) | 10 (2.7) | 9 (2.9) | 6 (2.4) |
| Mature B-cell neoplasms | 319 (57.7) | 242 (75.8) | 72 (40.2) | 247 (66.0) | 178 (57.9) | 141 (57.3) |
| CLL/SLL | 10 (1.8) | 4 | 1 (0.6) | 9 (2.4) | 3 (1.0) | 7 (2.8) |
| Mantle cell lymphoma | 5 (0.9) | 5 | 1 (0.6) | 4 (1.1) | 1 (0.3) | 4 (1.6) |
| Lymphoplasmacytic/Waldenstrom (LPL/Wald) | 3 (0.5) | 2 | — | 3 (0.8) | 3 (1.0) | — |
| Diffuse large B-cell lymphoma (DLBCL) | 116 (21.0) | 116 | 19 (10.6) | 97 (25.9) | 60 (19.5) | 56 (22.8) |
| Burkitt lymphoma (BL) | 4 (0.7) | 4 | — | 4 (1.1) | 3 (1.0) | 1 (0.4) |
| Marginal-zone lymphoma, nodal and extranodal (MZL) | 26 (4.7) | 26 | 5 (2.8) | 21 (5.6) | 15 (4.9) | 11 (4.5) |
| Follicular lymphoma (FL) | 22 (4.0) | 22 | 4 (2.2) | 18 (4.8) | 15 (4.9) | 7 (2.8) |
| Hairy cell leukemia (HCL) | 1 (0.2) | 1 | — | 1 (0.3) | — | 1 (0.4) |
| Plasma cell myeloma (PCM) | 124 (22.4) | 54 | 39 (21.8) | 85 (22.7) | 72 (23.5) | 52 (21.1) |
| Mature B-cell neoplasm, NOS | 8 (1.4) | 8 | 3 (1.7) | 5 (1.3) | 6 (2.0) | 2 (2.2) |
| Mature T-cell and NK-cell neoplasms | 108 (19.5) | 98 (90.7) | 61 (34.1) | 47 (12.6) | 57 (18.6) | 51 (20.7) |
| Mycosis fungoides/Sezary syndrome (MF/SS) | 4 (0.7) | 4 | 2 (1.1) | 2 (0.5) | 4 (1.3) | — |
| Peripheral T-cell lymphomas, not otherwise specified (PTCL, NOS) | 24 (4.3) | 24 | 15 (8.4) | 9 (2.4) | 13 (4.2) | 11 (4.5) |
| Angioimmunoblastic T-cell lymphoma (AITL) | 23 (4.2) | 23 | 5 (2.8) | 18 (4.8) | 12 (3.9) | 11 (4.5) |
| Enteropathy-associated T-cell lymphoma | 2 (0.4) | 2 | — | 2 (0.5) | 1 (0.3) | 1 (0.4) |
| Anaplastic large cell lymphoma, ALK positive and negative (ALCL) | 5 (0.9) | 5 | 1 (0.6) | 4 (1.1) | 1 (0.3) | 4 (1.6) |
| Adult T-cell leukemia/lymphoma (ATLL) | 38 (6.9) | 29 | 32 (17.9) | 6 (1.6) | 22 (7.2) | 16 (6.5) |
| T-cell large granular lymphocytic leukemia (LGL) | 2 (0.4) | 2 | 1 (0.6) | 1 (0.3) | 2 (0.7) | — |
| T-cell prolymphocytic leukemia (T-PLL) | 5 (0.9) | 5 | 2 (1.1) | 3 (0.8) | — | 5 (2.0) |
| Extranodal NK/T-cell lymphoma, nasal type | 1 (0.2) | 1 | — | 1 (0.3) | 1 (0.3) | — |
| Mature T-cell neoplasm, NOS | 4 (0.7) | 3 | 3 (1.7) | 1 (0.3) | 1 (0.3) | 3 (1.2) |
| Precursor cell neoplasms | 30 (5.4) | 18 (60.0) | 5 (2.8) | 25 (6.7) | 14 (4.6) | 16 (6.5) |
| B-cell | 7 (1.3) | 7 | 1 (0.6) | 6 (1.6) | 5 (1.6) | 2 (0.8) |
| T-cell | 8 (1.4) | 8 | 1 (0.6) | 7 (1.9) | 3 (1.0) | 5 (2.0) |
| Unknown lineage | 15 (2.7) | 3 | 3 (1.7) | 12 (3.2) | 6 (2.0) | 9 (3.7) |
| Malignant lymphoid neoplasm, non-Hodgkin, NOS | 22 (4.0) | 17 (77.3) | 9 (5.0) | 13 (3.5) | 12 (3.9) | 10 (4.1) |
| Malignant lymphoid neoplasm, NOS | 59 (10.7) | 3 (5.1) | 27 (15.1) | 32 (8.6) | 37 (12.1) | 22 (8.9) |
| Total | 553 (100) | 388 (70.2) | 179 (100) | 374 (100) | 307 (100) | 246 (100) |
| . | Cases (%) . | |||||
|---|---|---|---|---|---|---|
| Lymphoid neoplasm category . | Total . | . | City . | Sex . | ||
| Histologically verified . | Nagasaki . | Hiroshima . | Female . | Male . | ||
| Hodgkin lymphoma | 15 (2.7) | 10 (66.7) | 5 (2.8) | 10 (2.7) | 9 (2.9) | 6 (2.4) |
| Mature B-cell neoplasms | 319 (57.7) | 242 (75.8) | 72 (40.2) | 247 (66.0) | 178 (57.9) | 141 (57.3) |
| CLL/SLL | 10 (1.8) | 4 | 1 (0.6) | 9 (2.4) | 3 (1.0) | 7 (2.8) |
| Mantle cell lymphoma | 5 (0.9) | 5 | 1 (0.6) | 4 (1.1) | 1 (0.3) | 4 (1.6) |
| Lymphoplasmacytic/Waldenstrom (LPL/Wald) | 3 (0.5) | 2 | — | 3 (0.8) | 3 (1.0) | — |
| Diffuse large B-cell lymphoma (DLBCL) | 116 (21.0) | 116 | 19 (10.6) | 97 (25.9) | 60 (19.5) | 56 (22.8) |
| Burkitt lymphoma (BL) | 4 (0.7) | 4 | — | 4 (1.1) | 3 (1.0) | 1 (0.4) |
| Marginal-zone lymphoma, nodal and extranodal (MZL) | 26 (4.7) | 26 | 5 (2.8) | 21 (5.6) | 15 (4.9) | 11 (4.5) |
| Follicular lymphoma (FL) | 22 (4.0) | 22 | 4 (2.2) | 18 (4.8) | 15 (4.9) | 7 (2.8) |
| Hairy cell leukemia (HCL) | 1 (0.2) | 1 | — | 1 (0.3) | — | 1 (0.4) |
| Plasma cell myeloma (PCM) | 124 (22.4) | 54 | 39 (21.8) | 85 (22.7) | 72 (23.5) | 52 (21.1) |
| Mature B-cell neoplasm, NOS | 8 (1.4) | 8 | 3 (1.7) | 5 (1.3) | 6 (2.0) | 2 (2.2) |
| Mature T-cell and NK-cell neoplasms | 108 (19.5) | 98 (90.7) | 61 (34.1) | 47 (12.6) | 57 (18.6) | 51 (20.7) |
| Mycosis fungoides/Sezary syndrome (MF/SS) | 4 (0.7) | 4 | 2 (1.1) | 2 (0.5) | 4 (1.3) | — |
| Peripheral T-cell lymphomas, not otherwise specified (PTCL, NOS) | 24 (4.3) | 24 | 15 (8.4) | 9 (2.4) | 13 (4.2) | 11 (4.5) |
| Angioimmunoblastic T-cell lymphoma (AITL) | 23 (4.2) | 23 | 5 (2.8) | 18 (4.8) | 12 (3.9) | 11 (4.5) |
| Enteropathy-associated T-cell lymphoma | 2 (0.4) | 2 | — | 2 (0.5) | 1 (0.3) | 1 (0.4) |
| Anaplastic large cell lymphoma, ALK positive and negative (ALCL) | 5 (0.9) | 5 | 1 (0.6) | 4 (1.1) | 1 (0.3) | 4 (1.6) |
| Adult T-cell leukemia/lymphoma (ATLL) | 38 (6.9) | 29 | 32 (17.9) | 6 (1.6) | 22 (7.2) | 16 (6.5) |
| T-cell large granular lymphocytic leukemia (LGL) | 2 (0.4) | 2 | 1 (0.6) | 1 (0.3) | 2 (0.7) | — |
| T-cell prolymphocytic leukemia (T-PLL) | 5 (0.9) | 5 | 2 (1.1) | 3 (0.8) | — | 5 (2.0) |
| Extranodal NK/T-cell lymphoma, nasal type | 1 (0.2) | 1 | — | 1 (0.3) | 1 (0.3) | — |
| Mature T-cell neoplasm, NOS | 4 (0.7) | 3 | 3 (1.7) | 1 (0.3) | 1 (0.3) | 3 (1.2) |
| Precursor cell neoplasms | 30 (5.4) | 18 (60.0) | 5 (2.8) | 25 (6.7) | 14 (4.6) | 16 (6.5) |
| B-cell | 7 (1.3) | 7 | 1 (0.6) | 6 (1.6) | 5 (1.6) | 2 (0.8) |
| T-cell | 8 (1.4) | 8 | 1 (0.6) | 7 (1.9) | 3 (1.0) | 5 (2.0) |
| Unknown lineage | 15 (2.7) | 3 | 3 (1.7) | 12 (3.2) | 6 (2.0) | 9 (3.7) |
| Malignant lymphoid neoplasm, non-Hodgkin, NOS | 22 (4.0) | 17 (77.3) | 9 (5.0) | 13 (3.5) | 12 (3.9) | 10 (4.1) |
| Malignant lymphoid neoplasm, NOS | 59 (10.7) | 3 (5.1) | 27 (15.1) | 32 (8.6) | 37 (12.1) | 22 (8.9) |
| Total | 553 (100) | 388 (70.2) | 179 (100) | 374 (100) | 307 (100) | 246 (100) |